Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
NCT02926638 · SWOG Cancer Research Network · PHASE2/PHASE3 · terminated · last registry update 2020-03-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Drug company decided to terminate all sponsored clinical studies involving rilotumumab.” | – | Registry record, SWOG Cancer Research Network |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGFR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-03-17Results posted on the registry: SWOG Cancer Research Network, Afatinib Dimaleate + Cetuximab (NCT02438722)
- 2021-02-21Phase 3 first posted: AstraZeneca, Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin + Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin (NCT04765059)
- 2021-01-05Phase 3 first posted: Li Zhang, MD, Osimertinib + Pemetrexed (NCT04695925)
- 2020-07-27Phase 3 first posted: Janssen Research & Development, LLC, Amivantamab + Osimertinib (NCT04487080)
- 2020-07-02Phase 3 first posted: Sun Yat-sen University, RT plus Nimotuzumab + RT plus Cisplatin (NCT04456322)
- 2020-04-17Phase 3 first posted: AstraZeneca, Osimertinib + Cisplatin (NCT04351555)
- 2020-03-04Results posted on the registry: Eli Lilly and Company, Ramucirumab + Placebo (NCT02411448)
- 2020-01-30Phase 3 first posted: Yuhan Corporation, Lazertinib 240 mg/160 mg + Gefitinib 250 mg (NCT04248829)
- 2019-11-29Phase 3 first posted: National Cancer Institute (NCI), Bevacizumab + Osimertinib (NCT04181060)
- 2019-10-16Phase 3 first posted: Takeda, TAK-788 + Pemetrexed (NCT04129502)
- 2019-10-01Results posted on the registry: Boehringer Ingelheim, afatinib + paclitaxel (NCT02597946)
- 2019-07-29Phase 3 first posted: AstraZeneca, Osimertinib + Pemetrexed/Carboplatin (NCT04035486)
- 2019-07-15Results posted on the registry: Novartis Pharmaceuticals, Lapatinib + Trastuzumab (NCT01160211)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision